Compare Crispr Therapeutics AG (CRSP) vs iShares International Treasury Bond ETF (IGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares International Treasury Bond ETF — how do they compare? Crispr Therapeutics AG trades at $53.68 (market cap $4.88B), while iShares International Treasury Bond ETF trades at $39.71 (market cap $1.30B). The key difference: Crispr Therapeutics AG is far larger — about 3.8× iShares International Treasury Bond ETF's market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, iShares International Treasury Bond ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and iShares International Treasury Bond ETF for 92 Days on average.
| CRSP | IGOV | |
|---|---|---|
Market Cap | $4.88B | $1.30B |
Volume | 2,861,747 | 693,740 |
Sector | Health | Fixed Income |
52-Week High | $74.92 | $42.99 |
52-Week Low | $44.34 | $39.65 |
Typical Hold Time | 77 Days | 92 Days |
Enterprise Value | $3.30B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
IGOV trades at $39.67, down 0.08% with a bearish technical signal from moving averages, while oscillators are neutral. Key financial ratios are unavailable, limiting fundamental clarity. Recent news highlights rising global bond yields, which may impact interest rate-sensitive stocks.
The outlook is cautious due to missing financial data and bearish technicals. Risks include macroeconomic pressure from higher yields, while opportunities depend on future earnings visibility. Investors need updated financials to assess valuation and growth prospects accurately.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares International Treasury Bond ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and will invest at least 90% of its assets in fixed income securities included in the underlying index. The underlying index measures the performance of fixed-rate, local currency, investment-grade, sovereign bonds from certain developed markets. The fund is non-diversified.
Read more on IGOV →
